Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPL Regimen in Relapsed/Refractory DLBCL
NCT05335018Phase 2Active, not recruiting
- Sponsor
- Seoul National University Hospital
- Start
- May 2022
- Primary completion
- Nov 2025
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab, poseltinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Seoul National University Hospital. Started May 2022; status: active, not recruiting.
02
Drugs
glofitamabposeltinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05335018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05335018.